Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Current Deferred Revenue: 2020-2022

Historic Current Deferred Revenue for Therapeutics (RAPT) over the last 2 years, with Mar 2022 value amounting to $645,000.

  • Therapeutics' Current Deferred Revenue fell 79.43% to $645,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $645,000, marking a year-over-year decrease of 79.43%. This contributed to the annual value of $1.0 million for FY2021, which is 75.20% down from last year.
  • Per Therapeutics' latest filing, its Current Deferred Revenue stood at $645,000 for Q1 2022, which was down 36.52% from $1.0 million recorded in Q4 2021.
  • Therapeutics' Current Deferred Revenue's 5-year high stood at $6.0 million during Q2 2020, with a 5-year trough of $645,000 in Q1 2022.
  • Moreover, its 3-year median value for Current Deferred Revenue was $3.1 million (2021), whereas its average is $3.3 million.
  • Data for Therapeutics' Current Deferred Revenue shows a maximum YoY tumbled of 79.43% (in 2022) over the last 5 years.
  • Therapeutics' Current Deferred Revenue (Quarterly) stood at $4.1 million in 2020, then slumped by 75.20% to $1.0 million in 2021, then slumped by 79.43% to $645,000 in 2022.
  • Its Current Deferred Revenue stands at $645,000 for Q1 2022, versus $1.0 million for Q4 2021 and $1.5 million for Q3 2021.